<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ocular Melanoma - Adult Eye Cancer Guide | Vision Health Portal</title>
    <meta name="description"
        content="Comprehensive guide to ocular melanoma (uveal melanoma): most common primary intraocular malignancy in adults, pigmented choroidal mass often asymptomatic, plaque brachytherapy or enucleation treatment, liver metastasis monitoring.">
    <link rel="stylesheet" href="../style.css">
    <link rel="stylesheet" href="disease-style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css">
</head>

<body>
    <header>
        <a href="../index.html" class="logo">
            <i class="fas fa-eye"></i> VisionHealth
        </a>
        <nav>
            <ul>
                <li><a href="../index.html">Home</a></li>
                <li><a href="../tests/index.html">Vision Tests</a></li>
                <li><a href="../innovations.html">Innovations</a></li>
            </ul>
        </nav>
    </header>

    <div class="disease-hero">
        <h1>Ocular Melanoma (Uveal Melanoma)</h1>
        <p>Most Common Primary Eye Cancer in Adults</p>
        <span class="category"><i class="fas fa-tag"></i> Ocular Oncology</span>
    </div>

    <div class="disease-content-wrapper">
        <aside class="toc">
            <h3>Contents</h3>
            <ul>
                <li><a href="#overview">Overview</a></li>
                <li><a href="#types">Types & Location</a></li>
                <li><a href="#risk-factors">Risk Factors</a></li>
                <li><a href="#symptoms">Symptoms</a></li>
                <li><a href="#diagnosis">Diagnosis</a></li>
                <li><a href="#treatment">Treatment</a></li>
                <li><a href="#metastasis">Metastasis & Surveillance</a></li>
                <li><a href="#prognosis">Prognosis</a></li>
                <li><a href="#when-to-see">When to See a Doctor</a></li>
            </ul>
        </aside>

        <main class="disease-content">
            <section id="overview">
                <h2>What Is Ocular Melanoma?</h2>
                <p>Ocular melanoma, also called uveal melanoma, is a malignant cancer arising from melanocytes
                    (pigment-producing cells) in the uveal tract of the eye—comprising the iris, ciliary body, and
                    choroid. It is the most common primary intraocular malignancy in adults, though still rare, with an
                    incidence of ~5-7 cases per million per year. The majority (~90%) originate in the choroid (the
                    vascular layer beneath the retina), appearing as a pigmented (dark brown/black) or amelanotic
                    (non-pigmented) dome-shaped mass on dilated exam or imaging.</p>

                <p>Unlike cutaneous (skin) melanoma, uveal melanoma is not related to sun exposure. Risk factors include
                    light eye color, fair skin, and certain genetic conditions. Many patients are asymptomatic, with
                    tumors discovered incidentally during routine eye exams. Symptoms, if present, include blurred
                    vision, visual field defects, floaters, or flashes from retinal detachment. Diagnosis is primarily
                    clinical (dilated exam, ultrasound) without biopsy in most cases. Treatment depends on tumor size
                    and location: small tumors may be observed, medium tumors treated with plaque brachytherapy
                    (radioactive plaque), and large tumors or those threatening vision may require enucleation (eye
                    removal). A significant concern is metastasis—uveal melanoma has a predilection for spreading to the
                    liver (~50% develop metastasis within 10-15 years), necessitating lifelong surveillance.</p>

                <div class="key-facts">
                    <h3><i class="fas fa-info-circle"></i> Key Facts About Ocular Melanoma</h3>
                    <ul>
                        <li><strong>Most common primary eye cancer in adults</strong></li>
                        <li><strong>Arises from uveal tract:</strong> Mostly choroid (~90%).</li>
                        <li><strong>Not related to sun exposure</strong> (unlike skin melanoma).</li>
                        <li><strong>Risk factors: light eyes, fair skin</strong></li>
                        <li><strong>Often asymptomatic</strong> initially.</li>
                        <li><strong>Pigmented choroidal mass on exam/ultrasound</strong></li>
                        <li><strong>Treatment: observation, plaque brachytherapy, or enucleation</strong></li>
                        <li><strong>~50% develop liver metastasis</strong> → lifelong surveillance needed.</li>
                    </ul>
                </div>

                <p>Understanding ocular melanoma emphasizes the importance of regular eye exams and lifelong metastatic
                    surveillance after diagnosis.</p>
            </section>

            <section id="types">
                <h2>Types and Location</h2>

                <h3>By Location</h3>

                <h4>Choroidal Melanoma (~90%)</h4>
                <ul>
                    <li>Most common</li>
                    <li>Arises in choroid (vascular layer beneath retina)</li>
                    <li>Appears as dome-shaped or mushroom-shaped mass</li>
                    <li>May cause overlying retinal detachment</li>
                </ul>

                <h4>Ciliary Body Melanoma (~6%)</h4>
                <ul>
                    <li>Behind iris, difficult to visualize</li>
                    <li>Often larger at presentation (hidden location)</li>
                </ul>

                <h4>Iris Melanoma (~4%)</h4>
                <ul>
                    <li>Visible on anterior segment exam</li>
                    <li>Usually small, slow-growing</li>
                    <li>Best prognosis</li>
                </ul>

                <h3>By Pigmentation</h3>
                <ul>
                    <li><strong>Melanotic (pigmented):</strong> Dark brown/black; most common</li>
                    <li><strong>Amelanotic (non-pigmented):</strong> Pink/white; can be mistaken for other lesions</li>
                </ul>
            </section>

            <section id="risk-factors">
                <h2>Risk Factors</h2>

                <ul>
                    <li><strong>Light eye color:</strong> Blue or green eyes (higher risk than brown eyes)</li>
                    <li><strong>Fair skin, light hair</strong></li>
                    <li><strong>Caucasian ethnicity:</strong> Much more common in whites than other races</li>
                    <li><strong>Age:</strong> Median age ~60; rare in children</li>
                    <li><strong>Ocular melanocytosis/nevi:</strong> Pre-existing choroidal nevi (freckles) can transform
                        (rare)</li>
                    <li><strong>BAP1 tumor predisposition syndrome:</strong> Rare genetic condition; increased melanoma
                        risk</li>
                    <li><strong>NOT related to UV/sun exposure</strong> (unlike skin melanoma)</li>
                </ul>
            </section>

            <section id="symptoms">
                <h2>Recognizing the Symptoms</h2>

                <h3>Often Asymptomatic</h3>
                <ul>
                    <li>Many patients have no symptoms; tumor found on routine eye exam</li>
                </ul>

                <div class="symptoms-grid">
                    <div class="symptom-card">
                        <h4><i class="fas fa-cloud"></i> Blurred Vision</h4>
                        <p>If tumor involves macula or causes retinal detachment.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-map"></i> Visual Field Defect</h4>
                        <p>Shadow or blind spot from tumor or detached retina.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-bug"></i> Floaters and Flashes</h4>
                        <p>From retinal detachment.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-circle"></i> Visible Iris Mass</h4>
                        <p>If iris melanoma; pigmented spot on iris.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-eye-slash"></i> Gradual Vision Loss</h4>
                        <p>Slow enlargement of tumor.</p>
                    </div>

                    <div class="symptom-card">
                        <h4><i class="fas fa-ban"></i> Painless</h4>
                        <p>Typically painless unless very large causing glaucoma.</p>
                    </div>
                </div>
            </section>

            <section id="diagnosis">
                <h2>Diagnosis</h2>

                <h3>Dilated Fundus Examination</h3>
                <ul>
                    <li><strong>Appearance:</strong> Dome-shaped or mushroom-shaped pigmented (brown/black) or
                        amelanotic mass
                        <ul>
                            <li>May have overlying orange pigment (lipofuscin)</li>
                            <li>Subretinal fluid, retinal detachment</li>
                        </ul>
                    </li>
                    <li>Experienced ophthalmologist/ocular oncologist can often diagnose clinically</li>
                </ul>

                <h3>Ocular Ultrasound (B-Scan)</h3>
                <ul>
                    <li><strong>Key test:</strong> Shows characteristic dome-shaped lesion with low internal
                        reflectivity, choroidal excavation (Lund's sign)</li>
                    <li>Measures tumor thickness (important for staging and treatment planning)</li>
                </ul>

                <h3>Fluorescein Angiography, Indocyanine Green Angiography</h3>
                <ul>
                    <li>Assess tumor vascularity</li>
                </ul>

                <h3>Optical Coherence Tomography (OCT)</h3>
                <ul>
                    <li>Evaluate overlying retina, subretinal fluid</li>
                </ul>

                <h3>Fine Needle Aspiration Biopsy (Rarely)</h3>
                <ul>
                    <li>Usually NOT done (diagnosis primarily clinical)</li>
                    <li>May be performed if:
                        <ul>
                            <li>Diagnosis uncertain</li>
                            <li>To obtain tumor genetics (prognostic markers: chromosome 3, 8 status; BAP1 mutation) for
                                metastatic risk stratification</li>
                        </ul>
                    </li>
                </ul>

                <h3>Systemic Staging (To Rule Out Metastasis at Diagnosis)</h3>
                <ul>
                    <li>Liver imaging (MRI or CT)</li>
                    <li>Liver function tests</li>
                    <li>Chest imaging</li>
                </ul>
            </section>

            <section id="treatment">
                <h2>Treatment</h2>

                <p><strong>Goals:</strong> Control primary tumor, preserve eye/vision if possible, minimize metastatic
                    risk.</p>

                <h3>Observation (Small Tumors)</h3>
                <ul>
                    <li>Very small melanomas or suspicious nevi</li>
                    <li>Serial photography, ultrasound to monitor for growth</li>
                    <li>Treat if growth documented</li>
                </ul>

                <h3>Plaque Brachytherapy (Most Common for Medium Tumors)</h3>
                <ul>
                    <li><strong>Procedure:</strong> Radioactive plaque (usually iodine-125 or ruthenium-106) sutured to
                        sclera over tumor
                        <ul>
                            <li>Left in place 3-7 days</li>
                            <li>Delivers focused radiation to tumor</li>
                            <li>Removed in second surgery</li>
                        </ul>
                    </li>
                    <li><strong>Goal:</strong> Destroy tumor, preserve eye</li>
                    <li><strong>Success rate:</strong> ~85-90% local tumor control</li>
                    <li><strong>Complications:</strong> Radiation retinopathy, optic neuropathy, cataract, dry eye (can
                        cause vision loss over time)</li>
                </ul>

                <h3>Proton Beam Radiotherapy</h3>
                <ul>
                    <li>Alternative to plaque brachytherapy</li>
                    <li>External beam radiation with protons</li>
                    <li>Available at specialized centers</li>
                    <li>Similar efficacy and side effects as plaque</li>
                </ul>

                <h3>Enucleation (Eye Removal)</h3>
                <ul>
                    <li><strong>Indications:</strong>
                        <ul>
                            <li>Large tumors (>10 mm thickness) where radiation may not control tumor</li>
                            <li>Blind, painful eye from tumor</li>
                            <li>Optic nerve invasion</li>
                            <li>Patient preference</li>
                        </ul>
                    </li>
                    <li>Curative for primary tumor</li>
                    <li>Does NOT prevent metastasis (metastatic cells may already be in circulation)</li>
                    <li>Prosthetic eye fitted after healing</li>
                </ul>

                <h3>Local Resection (Rare)</h3>
                <ul>
                    <li>Surgical removal of tumor, preserving eye</li>
                    <li>High complication rate; not commonly performed</li>
                </ul>

                <h3>Laser or Cryotherapy (Very Small Tumors)</h3>
                <ul>
                    <li>Focal treatment for tiny lesions</li>
                </ul>
            </section>

            <section id="metastasis">
                <h2>Metastasis and Surveillance</h2>

                <h3>High Metastatic Potential</h3>
                <ul>
                    <li>Uveal melanoma metastasizes hematogenously (via bloodstream)</li>
                    <li><strong>Liver:</strong> Most common site (~90% of metastases involve liver)</li>
                    <li>Less commonly: lung, bone, skin</li>
                    <li>~50% of patients develop metastasis within 10-15 years</li>
                </ul>

                <h3>Prognostic Factors for Metastasis</h3>
                <ul>
                    <li><strong>Tumor size:</strong> Larger tumors → higher risk</li>
                    <li><strong>Ciliary body involvement</strong></li>
                    <li><strong>Epithelioid cell type</strong> (vs spindle cell)</li>
                    <li><strong>Genetic/molecular markers:</strong>
                        <ul>
                            <li>Monosomy 3 (loss of chromosome 3): high risk</li>
                            <li>Gain of chromosome 8q: high risk</li>
                            <li>BAP1 mutation: high risk</li>
                        </ul>
                    </li>
                    <li>Genetic testing (if biopsy performed) can stratify risk</li>
                </ul>

                <h3>Lifelong Surveillance for Metastasis</h3>
                <ul>
                    <li><strong>Essential:</strong> All uveal melanoma patients need lifelong monitoring</li>
                    <li><strong>Liver imaging:</strong> MRI or CT every 6-12 months initially, then annually</li>
                    <li><strong>Liver function tests</strong></li>
                    <li>Unfortunately, metastatic uveal melanoma is difficult to treat; no curative therapy currently
                    </li>
                    <li>Clinical trials investigating immunotherapy, targeted therapy for metastatic disease</li>
                </ul>
            </section>

            <section id="prognosis">
                <h2>Prognosis and Outcomes</h2>

                <h3>Local Tumor Control</h3>
                <ul>
                    <li>Excellent with plaque brachytherapy or enucleation (~85-95% control)</li>
                </ul>

                <h3>Vision Outcomes</h3>
                <ul>
                    <li>Variable; depends on tumor location and treatment side effects</li>
                    <li>Radiation can cause vision loss over time from complications (retinopathy, optic neuropathy)
                    </li>
                </ul>

                <h3>Metastasis and Survival</h3>
                <ul>
                    <li><strong>Overall survival:</strong> ~80% at 5 years, ~50-60% at 10-15 years (due to metastasis)
                    </li>
                    <li>Once metastatic disease develops, prognosis poor (median survival ~1 year without treatment;
                        modest improvement with new therapies)</li>
                    <li>Iris melanoma has best prognosis (low metastatic risk)</li>
                </ul>
            </section>

            <section id="when-to-see">
                <h2>When to See a Doctor</h2>

                <h3>See Eye Doctor If:</h3>
                <ul>
                    <li><strong>New visual symptoms:</strong> Blurred vision, floaters, flashes, shadow</li>
                    <li><strong>Pigmented spot noticed on iris</strong></li>
                    <li><strong>Routine eye exam recommended</strong> (many tumors asymptomatic)</li>
                </ul>

                <h3>Regular Eye Exams</h3>
                <ul>
                    <li>Especially if risk factors (light eyes, fair skin)</li>
                    <li>Many melanomas detected incidentally</li>
                </ul>

                <h3>Questions to Ask Your Doctor</h3>
                <ul>
                    <li>Do I have uveal melanoma?</li>
                    <li>What is the size and location?</li>
                    <li>What treatment do you recommend?</li>
                    <li>Can the eye and vision be preserved?</li>
                    <li>Should I have genetic testing of the tumor?</li>
                    <li>What is my risk of metastasis?</li>
                    <li>How often do I need surveillance imaging?</li>
                </ul>
            </section>

            <div class="alert-box info">
                <h4><i class="fas fa-lightbulb"></i> Bottom Line</h4>
                <p>Ocular melanoma (uveal melanoma) is the most common primary eye cancer in adults, arising from
                    melanocytes in the uvea—most commonly the choroid (~90%). It's not related to sun exposure; risk
                    factors include light eye color and fair skin. Many patients are asymptomatic, with tumors
                    discovered on routine eye exams as pigmented choroidal masses. Diagnosis is primarily clinical using
                    dilated exam and ocular ultrasound. Treatment depends on size: small tumors observed, medium tumors
                    treated with plaque brachytherapy (radioactive plaque) with ~85-90% control, and large tumors or
                    those threatening the eye require enucleation. The major concern is metastasis—uveal melanoma
                    spreads hematogenously to the liver in~50% of patients within 10-15 years. Genetic testing
                    (chromosome 3/8, BAP1) can stratify metastatic risk. All patients need lifelong liver surveillance
                    with imaging every 6-12 months. Prognosis for local tumor control is excellent, but overall survival
                    is impacted by metastatic disease, emphasizing the need for vigilant monitoring and ongoing research
                    into effective systemic therapies.</p>
            </div>

            <div class="related-diseases">
                <h3>Related Eye Conditions</h3>
                <div class="related-links">
                    <a href="retinoblastoma.html">Retinoblastoma</a>
                    <a href="choroidal-neovascularization.html">Choroidal Neovascularization</a>
                    <a href="macular-degeneration.html">Macular Degeneration</a>
                </div>
            </div>
        </main>
    </div>

    <footer>
        <div class="footer-content">
            <p>&copy; 2025 Vision Health Portal. All rights reserved.</p>
            <p class="designer-credit">Designed by RITIK DHAGE</p>
            <p style="font-size: 0.85rem; margin-top: 1rem; opacity: 0.8;">
                <i class="fas fa-info-circle"></i> This information is for educational purposes only and is not a
                substitute for professional medical advice, diagnosis, or treatment.
            </p>
        </div>
    </footer>
</body>

</html>